2019 European Society for Medical Oncology Congress Coverage
Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.
Research News:
Podcast Episodes:
Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage
Peter Schmid, M.D., Ph.D.
Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage
Leisha Emens, M.D.
Verzenio
Plus Faslodex Improves Survival in Metastatic
Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of
Menopausal Status
George W. Sledge, Jr., M.D.
"CDK4/6
Inhibitor Plus Hormonal Therapy Should Be First Treatment for
Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO
2019 Coverage
Dennis Slamon, M.D.
Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage
Jennifer Litton, M.D.
Heard in the Halls Mini Episodes:
Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019
Anne White, BS
People Satisfied With Decision to Use Scalp Cooling, Even If
It's Not Effective -- Heard in the Halls: Voices From ESMO 2019
Conleth Murphy, M.D.
Can we help guide you?
Create a profile for better recommendations
-
Breast Self-Exam
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
-
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
-
Breast Cancer Stages
The stage of a breast cancer is determined by the cancer’s characteristics, such as how large it...
